Citrate Oral Solution

Dovonex (calcipotriene solution) scalp solution 0.005%, is a colorless topical solution containing 0.005% calcipotriene in a vehicle of isopropanol (51% v/v) propylene 

---

Table 18.12 Hydrocortisone Eye Drops 1 % [17] Table 18.14 Magnesium Citrate Oral Solution 80 mg/mL [19] ...

Magnesium Citrate Oral Solution 80 mg/mL ENA (Table 18.14) is a supersaturated solution of magnesium citrate. The patient should be warned that crystallisation can take place after about 2 weeks, or earlier when the preparation is stored in the refrigerator. Magnesium citrate mixture USP has a similar formula. 

SODIUM CITRATE AND CITRIC ACID ORAL SOLUTION USP 473ML BOTTLE 6505010974766 BT 4.61 ... 

K-Lor oral solution (potassium bicarbonate/citrate) M in glassful of OJ and drink... 

Epivir oral solution is for oral administration. One milliliter (1 mL) of Epivir oral solution contains 10 mg lamivudine (10 mg/mL) in an aqueous solution and the inactive ingredients artificial strawberry and banana flavors, citric acid (anhydrous), methylparaben, propylene glycol, propylparaben, sodium citrate (dihydrate), and sucrose. 

Soluble, effervescent tablets are prepared by compression. In addition to active ingredients, they contain mixtures of acids (citric acid, tartaric acid) and sodium bicarbonate (NaHCOs) that release carbon dioxide when dissolved in water. The United States Pharmacopeia (USP) 24 includes the following seven monographs Acetaminophen for Effervescent Oral Solution Aspirin Effervescent Tablets for Oral Solution Potassium Bicarbonate Effervescent Tablets for Oral Solution Potassium Bicarbonate and Potassium Chloride for Effervescent Oral Solution Potassium Bicarbonate and Potassium Chloride Effervescent Tablets for Oral Solution Potassium and Sodium Bicarbonates and Citric Acid for Oral Solution and Potassium Chloride, Potassium Bicarbonate, and Potassium Citrate Effervescent Tablets for Oral Solution. ... 

Potassium citrate and citric acid oral solution, USP... 

Highly soluble salts (for example sodium fluoride, potassium chloride, potassium citrate) are preferably not prepared in a capsule at all, since rapid dissolution can result in a high local concentration that may be harmful to the mucosa of the gastro-intestinal tract. An enteric coating on capsules and tablets can protect the gastric mucosa from irritating active substances. But the preparation of an oral solution of the active substance may be a better alternative. 

Death. Aluminum is not thought to be life-threatening to healthy humans. Studies of people receiving extremely high doses of oral aluminum in antacids have not shown any human deaths from aluminum. However, in the past, aluminum-related deaths have been reported for persons with renal disease dialyzed with aluminum -containing solutions, uremic patients exposed to dietary aluminum hydroxide to treat hyperphosphatemia and sodium citrate to correct metabolic acidosis (Kirschbaum and Schoolwerth 1989), and workers exposed by inhalation to fine powders of aluminum metal. Only very large doses (hundreds of mg/kg) of aluminum cause death in laboratory animals. 

After ingestion, sodium citrate is absorbed and metabolized to bicarbonate. Although it is generally regarded as a nontoxic and nonirritant excipient, excessive consumption may cause gastrointestinal discomfort or diarrhea. Therapeutically, in adults, up to 15 g daily of sodium citrate dihydrate may be administered orally, in divided doses, as an aqueous solution to relieve the painful irritation caused by cystitis. 

Tripelennamlne Gtrate, USP. The oily free ba.se of iripelcnnaminc citrate, 2- benzyl 2-(dimethylamino)etliyl -jminolpyridine citrate (1 1). PBZ (Pyribenzamine Citrate), ii available as the less bitter nuin(M.-itrute salt, which is a while aystallinc powder freely soluble in water and in alcohol. A 1% solution has a pH of 4.2.S. For oral administration in liquid dose forms, the citrate salt is less biller and thus mote palatable than the hydrochloride. Because of the differ-mce in molecular weights, the doses of the two salts must he equaled—30 mg of the citrate salt is equivalent to 20 mg of the hydrochloride salt. 

In PROP deficiency, a trial of oral biotin (5-20 mg/d) is often given [3, 5, 7]. The benefit of supplemental biotin has been debated, and if an improvement in metabolic parameters is not observed with supplementation, discontinuation is suggested [5]. Other therapies, such as metronidazole and citrate solutions for PROP, may also be prescribed [5,7]. 

Fig. 118. Beginning of the formation of a multinucleate giant cell by fusion of mononuclear alveolar phagocytes. Female white rat (breeder Winkelmann, Borchen-Kirchborchen) medicated with 125 mg dexpanthenol in a 5 % aqueous solution per kg body weight x day during a 5-day work week. Oral application took place from April 17 to August 14, 1967 for a total of 82 days. Fixed on August 14, 1967 under methi-tural anaesthesia by intratracheal instillation of 2.5 % gluta-raldehyde in phosphate buffer (pH 7.4) before opening the thorax. Postfixation with 1 % osmium tetroxide in phosphate buffer (pH 7.4). Contrasted en bloc for 12 h with 0.5 % uranyl acetate in 70% ethanol. Embedded in a 2 8 mixture of methyl and butyl methacrylate. Sectioned at 50 nm. Lead citrate after Reynolds (1963). Plate 5/05...

---